Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | $210.78M |
| Net Income (Most Recent Fiscal Year) | $65.63M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.70 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.57 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.56 |
| Pre-Tax Margin (Trailing 12 Months) | -96.76% |
| Net Margin (Trailing 12 Months) | -92.30% |
| Return on Equity (Trailing 12 Months) | -17.81% |
| Return on Assets (Trailing 12 Months) | -14.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.98 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.04 |
| Earnings per Share (Most Recent Fiscal Year) | $1.68 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.78 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 38.04M |
| Free Float | 34.95M |
| Market Capitalization | $214.91M |
| Average Volume (Last 20 Days) | 0.26M |
| Beta (Past 60 Months) | -0.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.11% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |